Liu Y, Zhang Y, Li Y, et al. - The safety and efficacy of implanting Nano+ (Lepu Medical, Beijing, China) stent, a novel polymer-free sirolimus-eluting stent polymer that uses nanoporous stent surface technology to regulate drug-delivery, were investigated in all-comer patients at the 1-year follow-up. The multicenter and prospective NANO registry comprised of 2,481 consecutive patients. Presentation with acute myocardial infarction (AMI) was reported for up to 40.2% of patients. Among the 2,904 lesions, a total of 63.9% were the American College of Cardiology/American Heart Association type B2 or C lesions. Observations revealed excellent 1-year clinical outcomes for Nano+ polymer-free SES implantation in an all-comer patient population. Independent predictors of 1-year target lesion failure were diabetes mellitus, AMI, left ventricular ejection fraction < 40% and long lesions (> 40 mm).